Rezultati pretraživanja
  1. prije 14 sati
  2. 27. sij

    Good luck with that. At least for RNAi, it was industry that took all of the risk and did 98% of work to turn it into a medical reality.

  3. 21. sij

    Jefferies EU 2020 outlook Top picks: Possible winners from binary events: Least preferred: ( ) Other mentions:

    Prikaži ovu nit
  4. 21. sij

    Arrowhead ( ) is down 8% with that new underperform rating Amazing what something like that can do

  5. 21. sij

    Silence Therapeutics once specialized in using lipoplexes to deliver systemically to lung. But that was in past, now GalNAc-focused. I bet, Wuhan coronavirus-targeting RNAi triggers being produced by some as we speak.

    Prikaži ovu nit
  6. 21. sij
    Prikaži ovu nit
  7. 20. sij
  8. 17. sij

    Nonclinical Safety Profile of Revusiran, a 1st-Generation GalNAc-siRNA Conjugate for Treatment of Hereditary Transthyretin-Mediated Amyloidosis

  9. 15. sij
    Odgovor korisniku/ci

    The value of anything is what someone else will pay for it, in this case paid 9.7B for one drug, no platform was part of the deal as you point out. Makes quite undervalued by comparison

  10. 10. sij

    He didn’t even get a platform with it. I would rather have a pre clinical lp(a) programme and an RNAi platform for $1bn. Like 🤡

  11. 7. sij
  12. 7. sij

    Silence Therapeutics provides business update - Signed tech eval deal with for siRNA molecules for undisclosed target - Exploring multiple BD deals with large - Opening US subsidiary in 2020 PR:

    Prikaži ovu nit
  13. 2. sij

    2020 portfolio, in order position size. Up over 320% in 2109 85% (was close to 100% Dec 2nd) CASH Thinking of adding , and

  14. 2. sij
    Odgovor korisnicima i sljedećem broju korisnika:

    How do you think compliance for the ASO will be impacted by the need for such frequent doing, versus RNAi competition which will only be dosed quarterly? Analogous to PCSK9 siRNA Inclisiran dosing at 2x/yr vs 2x/mo for the mAbs

  15. 2. sij
    Odgovor korisniku/ci

    Weekly dosing!! I’m sorry but that’s a total non starter for preventative CVD. An injection every week for an asymptomatic patient? Great target and data but this is now a huge opportunity for RNAi companies.

  16. 31. pro 2019.

    My 2019 review sneak peak, when it comes to investing: ended the year with $249k AUM, 242% Time Weighted Return. . More detailed blog post will come in few days.

    Prikaži ovu nit
  17. 17. pro 2019.
    Odgovor korisniku/ci

    The trend is starting to reveal itself as drugs continue to show great results and market realizes that success rate will be significantly higher than current biopharma rates. Discount rates going down

  18. 10. pro 2019.

    here is link to article, podcast too.

  19. 4. pro 2019.

    📈🇬🇧Silence Therapeutics YTD perf is now 4-digit, with... +1025% 🔥🔥🔥 Well done to the long bulls.

  20. 28. stu 2019.
    Odgovor korisniku/ci

    Since you took long positions in , in which your short thesis for applies in exactly the same way; I’m thinking you’re actually not too concerned about AAT safety, but instead think the SP has run up to quickly. Highlighting the mild AE’s as a fear tactic 😉

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.